Welcome to our dedicated page for Conmed news (Ticker: CNMD), a resource for investors and traders seeking the latest updates and insights on Conmed stock.
Conmed Corporation (CNMD) delivers innovative medical technologies that enhance surgical outcomes and patient care worldwide. This dedicated news hub provides investors and healthcare professionals with timely updates on corporate developments, financial performance, and product advancements shaping the medical device sector.
Access authoritative information on CNMD's latest earnings reports, regulatory milestones, and strategic partnerships. Our curated collection includes press releases detailing new product launches in orthopedics, general surgery, and patient monitoring systems, along with updates on global market expansion initiatives.
Stay informed about critical developments through verified announcements directly from Conmed Corporation and third-party analysis. This resource enables stakeholders to track the company's progress in advancing minimally invasive surgical techniques and improving clinical workflows across healthcare institutions.
Bookmark this page for streamlined access to CNMD's evolving role in medical technology innovation. Regularly updated content supports informed analysis of the company's market position and long-term growth trajectory within the competitive healthcare solutions landscape.
CONMED Corporation (NYSE: CNMD) has announced a quarterly cash dividend of $0.20 per share, payable on April 5, 2021 to shareholders on record as of March 15, 2021.
CONMED is a medical technology company that provides surgical devices for minimally invasive procedures, serving various specialties including orthopedics and neurosurgery. The announcement reflects the company's ongoing commitment to returning value to shareholders.
CONMED Corporation (NYSE: CNMD) announced participation of Curt R. Hartman, Chair of the Board and CEO, alongside Todd W. Garner, CFO, in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference. The event is scheduled for 9:20 a.m. ET on February 25, 2021.
The live webcast will be available in the ‘Investors’ section of their website, and a replay will be accessible post-event. CONMED is a provider of surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) reported Q4 2020 sales of $252.8 million, down 4.5% year-over-year, with domestic revenue decreasing 0.7% and international revenue falling 9.1%. Diluted EPS rose to $0.81 from $0.49 in Q4 2019, while adjusted EPS decreased from $0.90 to $0.84. For the full year, sales were $862.5 million, a 9.7% decline, and diluted EPS was $0.32 versus $0.97 in 2019. The company expects 2021 revenue between $975 million and $1.02 billion, with adjusted EPS forecasted at $2.85 to $3.05.
CONMED Corporation (CNMD) will report its fourth quarter and full year 2020 financial results on January 27, 2021, post-market close. A conference call hosted by management will take place at 4:30 p.m. ET to discuss these results. Participants can join the call by dialing specific numbers provided or via a webcast accessible through the company’s website. A recording of the call will be available for one week following the event. The company specializes in surgical devices for minimally invasive procedures across various medical specialties.
CONMED Corporation (NYSE: CNMD) announces that Curt R. Hartman and Todd W. Garner will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 10:00 a.m. ET. The presentation will be accessible via a live webcast on the Company's website at www.conmed.com, with a replay available post-event. CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties, including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) announced participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. CEO Curt R. Hartman and CFO Todd W. Garner will feature in a pre-recorded fireside chat, available from 10:00 a.m. ET on November 23 until December 3, 2020. Interested parties can access the chat through the conference site or via the Company’s website. CONMED specializes in surgical devices for minimally invasive procedures across various specialties including orthopedics and neurosurgery.
CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share, scheduled for payment on January 5, 2021, to shareholders of record as of December 15, 2020. This dividend reflects the company's commitment to returning value to its shareholders. As a medical technology company, CONMED offers surgical devices for various medical specialties including orthopedics, general surgery, and more. The announcement signals confidence in the company's ongoing financial health and operational stability.
CONMED Corporation (NYSE: CNMD) announced a change in its presentation time at the Jefferies Virtual London Healthcare Conference to 11:25 a.m. ET on November 18, 2020. Todd W. Garner, Executive Vice President and CFO, will represent the company. The presentation will be available via a live webcast on the company's website, with a replay accessible afterward.
CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties, including orthopedics, general surgery, and more. For further details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) announced that Todd W. Garner, Executive Vice President and CFO, will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:25 p.m. ET. A live webcast of the presentation will be available in the ‘Investors’ section on the company’s website, with a replay accessible post-event. CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties including orthopedics and neurosurgery. For further details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported Q3 2020 financial results with sales of $237.8 million, an increase of 1.8% year-over-year. Domestic revenues grew by 4.7%, while international revenues fell by 1.7%. GAAP diluted EPS was $0.23, unchanged from Q3 2019, but adjusted diluted EPS rose to $0.88 from $0.62. The company noted ongoing operational challenges due to COVID-19 but expressed confidence in achieving future growth. However, financial guidance remains unavailable due to pandemic uncertainties.